Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup

Ryan Cross

Senior Science Correspondent

Andrew Dunn

Senior Biopharma Correspondent

Earlier Tuesday, Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech’s biggest-ever startup launches: Xaira Therapeutics, which has …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup

Ryan Cross

Senior Science Correspondent

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Ex­clu­sive: Marc Tessier-Lav­i­gne on leav­ing Stan­ford and join­ing biotech’s new AI mega-start­up

Senior Science Correspondent

Senior Biopharma Correspondent

Sign up to read this article for free.

Exclusive: Marc Tessier-Lavigne on leaving Stanford and joining biotech’s new AI mega-startup